{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-positive+Solid+Tumor&page=2", "query": { "condition": "HER2-positive Solid Tumor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-positive+Solid+Tumor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T14:56:42.817Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04319757", "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Cancer", "Solid Tumor", "HER2-positive Gastric Cancer", "HER2-positive Metastatic Breast Cancer" ], "interventions": [ { "name": "ACE1702", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acepodia Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-06-24", "completion_date": "2024-07-15", "has_results": false, "last_update_posted_date": "2024-12-05", "last_synced_at": "2026-07-23T14:56:42.817Z", "location_count": 2, "location_summary": "Chicago, Illinois • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04319757" }, { "nct_id": "NCT07318805", "title": "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer (HR+/ HER2-)", "Colorectal Cancer", "Metastatic Colorectal Adenocarcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "PF-08032562", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2025-12-23", "completion_date": "2030-04-14", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-23T14:56:42.817Z", "location_count": 13, "location_summary": "Duarte, California • Grand Rapids, Michigan • Long Island City, New York + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Long Island City", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07318805" }, { "nct_id": "NCT01245205", "title": "Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Akt inhibitor MK2206", "type": "DRUG" }, { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2010-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-10-23", "last_synced_at": "2026-07-23T14:56:42.817Z", "location_count": 2, "location_summary": "Sioux Falls, South Dakota • Madison, Wisconsin", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01245205" }, { "nct_id": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Carcinoma", "Advanced Colon Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Gastric Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Salivary Gland Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "HER2-Positive Breast Carcinoma", "Malignant Hepatobiliary Neoplasm", "Metastatic Breast Carcinoma", "Metastatic Colon Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Salivary Gland Carcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Major Salivary Gland Cancer AJCC v8", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Major Salivary Gland Cancer AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Unresectable Breast Carcinoma", "Unresectable Colon Carcinoma", "Unresectable Colorectal Carcinoma", "Unresectable Endometrial Carcinoma", "Unresectable Gastric Carcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Salivary Gland Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2021-08-09", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-07-23T14:56:42.817Z", "location_count": 23, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 16 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704661" }, { "nct_id": "NCT05054374", "title": "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Cancer Stage IV", "HER2-negative Breast Cancer", "Solid Carcinoma", "MEK1 Gene Mutation", "MEK2 Gene Mutation", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-09-14", "completion_date": "2023-10-26", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-07-23T14:56:42.817Z", "location_count": 4, "location_summary": "Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more", "locations": [ { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05054374" }, { "nct_id": "NCT07288359", "title": "Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced HR+/HER2- Breast Cancer", "Advanced CCNE1-amplified Solid Tumors", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "GVV858", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 205, "start_date": "2025-12-29", "completion_date": "2031-05-09", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-23T14:56:42.817Z", "location_count": 2, "location_summary": "Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288359" }, { "nct_id": "NCT00741260", "title": "Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2008-12-09", "completion_date": "2018-06", "has_results": true, "last_update_posted_date": "2018-09-05", "last_synced_at": "2026-07-23T14:56:42.817Z", "location_count": 12, "location_summary": "Mobile, Alabama • Long Beach, California • Los Angeles, California + 9 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Post Falls", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT00741260" }, { "nct_id": "NCT04492488", "title": "A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Advanced or Metastatic Gastric Cancer", "Advanced or Metastatic Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "MRG002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai Miracogen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2021-05-24", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-07-23T14:56:42.817Z", "location_count": 2, "location_summary": "Orange, California • Houston, Texas", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04492488" }, { "nct_id": "NCT01576666", "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dose Escalation", "Safety", "Preliminary Efficacy", "Advanced Solid Tumors", "Metastatic Breast Cancer", "Advanced Pancreatic Adenocarcinoma", "Metastatic Colorectal Cancer", "Recurrent Glioblastoma Multiforme", "Gastric Cancer", "Gastroesophageal Junction Cancer", "Triple Negative Metastatic Breast Cancer", "Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer" ], "interventions": [ { "name": "LDE225", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2012-07", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-07-23T14:56:42.817Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01576666" }, { "nct_id": "NCT00526045", "title": "Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Hematologic Neoplasms" ], "interventions": [ { "name": "AUY922 2 mg/m2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2007-07", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-07-23T14:56:42.817Z", "location_count": 7, "location_summary": "Los Angeles, California • Augusta, Georgia • Boston, Massachusetts + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT00526045" } ] }